Efalizumab
- Generic Name
- Efalizumab
- Drug Type
- Biotech
- CAS Number
- 214745-43-4
- Unique Ingredient Identifier
- XX2MN88N5D
- Background
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
- Indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Moderate to Severe Chronic Plaque Psoriasis
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00051662
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2002-04-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Registration Number
- NCT00034203
- Locations
- 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The San Diego Arthritis and Osteoporosis Medical Clinic, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.